This website is written by experts in Pharmaceutical Industry Manufacturing Research and Development and Regulatory Affairs Since 2008 and in 2011 Awarded as one of top 10 websites across world in Pharmaceutical Manufacturing Regulatory
USFDA WHO GMP Guidelines Pharmaceutical Regulations Information about Pharma Quality Managment System Validations Process Validation Cleaning Validation Equipment Qualification Equipment Process Validation Computer System Validation Sterile Product Manufacturing Guidelines Media fill guideline Aseptic Techniques in Sterile dosage form Clean Room Clean Room Classification Guidelines on Area Qualification HVAC AHU HEPA Filter HEPA Filter integrity testing and leak test

Friday, June 3, 2022

New Options for HIV positive patients treatment will be available soon for daily dose of ART in HIV positive patients treatment

Treatment of HIV positive patients requires daily dose of ART (Antiretroviral Therapy) medicines which are a combination of many anti-retroviral drugs combined together. Combination ART drugs prescribed to HIV positive patients to keep their viral load under control and are very effective in providing protection against HIV to patients.

Daily dose of antiretroviral medicines also has some side effects like  ART related hyperlipidemia and heart diseases ( Cardiovascular effect) nausia and so on, because of which many patients discontinue ART. which is a major reason for development of more complex, serious HIV infection.
Inorder to provide a solution to this, Broadly neutralising Antibody (bNAb) treatment is explored, in a study it is found that if more than two Broadly neutralising antibodies are given to patients in initial stage monthly once and ART is skipped, patients HIV viral load is kept under control, result of protection is similar to ART treatment, therefore this combination of broadly neutralising Antibodies provide an option to long tern ART treatment and relief from the side effects of ART.
Broadly neutralising antibodies do not pose any side effects as they are required to be taken only once in a month as compared to ART which is required to be taken daily.
Anthony S. Fauci, M.D., NIAID director and chief of NIAID’s Laboratory of Immunoregulation and Michael C. Sneller, M.D., and Tae-Wook Chun, Ph.D., also of NIAID’s have conducted the study and found that the patients who do not have antibody resistant HIV virus load in their body can opt for this treatment. Patients have to take once a month infusion of a cocktail of Broadly neutralising Antibody (bNAb). These patients need not take ART drugs.
In future this approach which will have more Broadly neutralising Antibody (bNAb) targeting as many sites on viral particles will be available and this will be one of best option for treatment of HIV positive patients.



No comments:

Pharma Guidelines Most Read

.

Readers Visit Number

This website is Authentic Source of Pharmaceutical Guidelines

This website is Authentic Source of Pharmaceutical Guidelines

Pharma Validations Quality Management System USFDA Guidelines WHO GMP Guidelines New Drug Update





This website consist of detail Information about Pharma Guidelines Pharma Regulatory Affairs USFDA Guidelines WHO Guidelines Pharmaceutical Quality Management System Pharma Validations Process Validation Cleaning Validation Equipment Qualification Equipment Process Validation Computer System Validation Sterile Product Manufacturing Guidelines Media fill guideline Aseptic Techniques in Sterile dosage form Clean Room Clean Room Classification Guidelines on Area Qualification HVAC AHU HEPA Filter HEPA Filter integrity testing and leak test